Patents by Inventor Guy Georges

Guy Georges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIFAB-CONTORSBODY
    Publication number: 20240158533
    Abstract: Herein is reported a multispecific antibody comprising two circular fusion polypeptides each of them comprising a VH/VL-pair and thereby a first and a second binding site, whereby a third VH/VL-pair and thereby a third binding site is formed by the associated of the two circular fusion polypeptides.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 16, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Steffen DICKOPF, Guy GEORGES, Irmgard THOREY
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240117029
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240083993
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • Antibodies binding to NKG2D
    Publication number: 20240067734
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • ANTI-BRDU ANTIBODIES AND METHODS OF USE
    Publication number: 20240043564
    Abstract: The invention provides anti-BRDU antibodies and methods of using the same.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Guy GEORGES, Johannes AUER, Wilma LAU
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20230399391
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: December 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine lmhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • Anti-VEGF antibodies and methods of use
    Patent number: 11820816
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: November 21, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • ANTI-HBV ANTIBODIES AND METHODS OF USE
    Publication number: 20230340081
    Abstract: The invention provides anti-S-HBs antibodies and methods of using the same.
    Type: Application
    Filed: June 8, 2021
    Publication date: October 26, 2023
    Inventors: Maryline BOURGINE, Maxime BERETTA, Hugo MOUQUET, Verena HEHLE, Stanislas POL, Hélène STRICK-MARCHAND, Malika AIT-GOUGHOULTE, Nadège PELLETIER, Jens FISCHER, Guy GEORGES, Tilman SCHLOTHAUER, Erwin VAN PUIJENBROEK, Wouter DRIESSEN
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • ANTI-TIM3 ANTIBODIES AND METHODS OF USE
    Publication number: 20230279109
    Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.
    Type: Application
    Filed: March 20, 2023
    Publication date: September 7, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
  • Bispecific anti-CCL2 antibodies
    Patent number: 11739142
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
    Publication number: 20230220071
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Three-dimensional structure-based humanization method
    Patent number: 11680110
    Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 20, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Guy Georges, Stefan Klostermann, Wolfgang Schaefer
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230183349
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 15, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Laura CODARRI DEAK, Stefan DENGL, Sebastian FENN, Jens FISCHER, Guy GEORGES, Christian KLEIN, Viktor LEVITSKI, Valeria LIFKE, Oliver PLOETTNER, Stefan SEEBER, Barbara WEISER, Ildiko WUENSCHE, Adrian ZWICK
  • Anti-BRDU antibodies and methods of use
    Patent number: 11673968
    Abstract: The invention provides anti-BRDU antibodies and methods of using the same.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Johannes Auer, Wilma Lau
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230143310
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 11608376
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti